Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-α in the guinea-pig papillary muscle

Cardiovascular Research

Volumn 41, Issue 3, 1999, Pages 611-619

  Alloatti, Giuseppe ^a   Penna, Claudia ^a   De Martino, Antonella ^a   Montrucchio, Giuseppe ^b   Camussi, Giovanni ^c  

^a Laboratorio di Fisiologia Generale   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiac action potential; Cardiac contractility; Nitric oxide; Papillary muscle; Platelet activating factor; Tumor necrosis factor

Indexed keywords

[2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; BEPAFANT; BETA ADRENERGIC RECEPTOR; INDOMETACIN; N(G) NITRO DEXTRO ARGININE; N(G) NITROARGININE; NITRIC OXIDE; NITRITE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOCARDIUM; GUINEA PIG; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; NONHUMAN; PRIORITY JOURNAL;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; AZEPINES; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; GUINEA PIGS; HEART; INDOMETHACIN; MYOCARDIAL CONTRACTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPID ETHERS; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PROPRANOLOL; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032993839     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00250-8     Document Type: Article

References (40)

1. Ungureanu-Longrois D., Balligand J.-L., Kelly R.A., Smith T.W. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol. 27:1995;155-167.
2. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 9:1993;317-343.
3. Kumar A., Thota V., Dee L.et al. Tumor necrosis factor α and interleukin 1ß are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 183:1996;949-958.
4. Smith S.C., Allen P.M. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res. 70:1992;856-863.
5. Arbustini E., Grasso M., Diegoli M.et al. Expression of human tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am J Pathol. 139:1991;709-715.
6. Maury C.P.J., Teppo A.M. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J Intern Med. 225:1989;233-236.
7. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med. 223:1990;236-241.
8. Torre-Amione G., Kapadia S., Lee J.et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human myocardium. Circulation. 93:1996;704-711.
9. Finkel M.S., Oddis C.V., Jacobs T.D.et al. Negative inotropic effects of cytokine on the heart mediated by nitric oxide. Science. 257:1992;387-389.
10. i and contractility in isolated adult ventricular rabbit myocytes. Am J Physiol. 271(Heart Circ Physiol 40):1996;H1449-H1455.
11. Yokoyama T., Vaca L., Rossen R.D.et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
12. Stein B., Frank P., Schmitz W., Scholz H., Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol. 28:1996;1631-1639.
13. Camussi G., Bussolino F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 166:1987;1390-1404.
14. Levi R., Burke J.A., Hattori Z.G.G.et al. Acetyl glyceryl ether phosphorylcholine (AGEPC): a putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 54:1984;117-124.
15. Alloatti G., Montrucchio G., Mariano F.et al. Effect of platelet-activating factor on human cardiac muscle. Int Arch Allergy Appl Immunol. 79:1986;108-112.
16. Brutsaert D.L., Meulemans A.L., Sipido K.R., Sys S.U. Effects of damaging endocardial surface on the cardiac performance of isolated cardiac muscle. Circ Res. 62:1988;358-366.
17. G-nitro arginine (L-NOARG), a novel, L-arginine reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol. 99:1990;408-412.
18. Heuer H.O., Casals-Stenzel J., Muacevic G., Weber K.H. Pharmacological activity of bepafant (WEB 2170), a new and selective tetrazepinoic antagonist of platelet-activating factor. J Pharmacol Exp Ther. 255:1990;962-968.
19. Terashita Z., Tsushima S., Yoshioa Y.et al. CV 3988: a specific antagonist of platelet-activating factor (PAF). Life Sci. 32:1983;1975-1979.
20. Schmidt H.H., Warner T.D., Nakane M., Forstermann U., Murad F. Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. J Pharmacol Exp Ther. 41:1992;615-624.
21. Montrucchio G., Lupia E., Battaglia E.et al. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med. 180:1994;377-382.
22. Camussi G. Interactive effects of tumor necrosis factor and platelet activating factor in the pathogenesis of glomerular injury. Lab Invest. 70:1994;435-436.
23. Camussi G., Alloatti G., Montrucchio G., Meda M., Emanuelli G. Effect of platelet-activating factor on guinea-pig papillary muscle. Experientia. 40:1984;697-699.
24. Brady A.J.B., Warren J.B., Poole-Wilson P.A., Williams T.J., Harding S.E. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 265(Heart Circ Physiol 34):1993;H176-H182.
25. Mohan P., Brutsaert D.L., Paulus W.J., Sys S.U. Myocardial contractile response to nitric oxide and cGMP. Circulation. 93:1996;1223-1229.
26. Xie Y., Wolin M.S. Role of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation. Circulation. 94:1996;2580-2586.
27. Whaler G.M., Dollinger S.J. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol. 268(Cell Physiol 37):1995;C45-C54.
28. Gollasch M., Ignatieva V., Kobrinsky E., Vornowitsky E., Zaborowkaya L. Electrophysiological mechanisms responsible for the action of PAF in guinea-pig myocardium. Relation to the putative membrane signalling processes of PAF. J Lipid Mediators. 3:1991;139-159.
29. Janero D.R., Burghardt C. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte). Res Commun Chem Pathol Pharmacol. 67:1990;201-218.
30. Evans D.A., Jacobs D.O., Revhaug A., Wilmore D.W. The effects of tumor necrosis factor and their selective inhibition by ibuprofen. Ann Surg. 209:1989;312-321.
31. Wilcox P., Milliken C., Bressler B. High-dose tumor-necrosis factor α produces an impairment of hamster diapragm contractility. Am J Respir Crit Care Med. 153:1996;1611-1615.
32. Cervoni P., Herzlinger H.E., Lai F.M., Tanikella T.K. Aortic vascular and atrial response to 1-O-octadecyl-2-acetyl-glyceryl-3-phosphocholine. Br J Pharmacol. 79:1983;667-671.
33. Balligand J.-L., Kobzik L., Han X.et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (Type III) nitric oxide synthase in cardiac myocytes. J Biol Chem. 270:1995;14582-14586.
34. Szabó C., Wu C.C., Mitchell J.A.et al. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res. 73:1993;991-999.
35. Montrucchio G., Lupia E., De Martino A.et al. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-α Am J Pathol. 151:1997;557-564.
36. Caplan M.S., Hedlund E., Hill N., MacKerndrick W. The role of endogenous nitric oxide and platelet-activating factor in hypoxia-induced intestinal injury in rats. Gastroenterology. 106:1994;346-352.
37. Herbertson M.J., Werner H.A., Walley K.H. Platelet-activating factor antagonism improves ventricular contractility in endotoxemia. Crit Care Med. 25:1997;221-226.
38. Gurevitch J., Frolkis I., Yuhas Y.et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol. 28:1996;247-252.
39. Montrucchio G., Alloatti G., Tetta C. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol. 256(Heart Circ Physiol 25):1989;H1236-H1246.
40. Lefer A.M., Tsao P., Aoki N., Palladino M.A. Jr. Mediation of cardioprotection by transforming growth factor-β Science. 249:1990;61-64.